IRCCS - Ospedale San Raffaele

Milano 8 trials 4 recruiting

8 Registered trials

4 Currently recruiting

Organisation

IRCCS - Ospedale San Raffaele

Location

Milano, Italy

Identifier

ORL-000006294

Address

Via Olgettina 60, 20132, Italy

Departments

Dipartimento Cardio Toracico Cardiovascolare
Dipartimento di Oncologia Medica
Medical Oncology
Neurology
Oncologia Medica
U.O. Nefrologia e Dialisi
UO di Nefrologia e Dialisi

Clinical trials at this site (8)

Search interface

A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending

2024-515448-22-00 Parkinson 4
A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
Single-blinded randomized investigator-initiated controlled trial to assess the efficacy of colchicine to treat patients with cardiomyopathy… Pending

2024-517945-14-00 Inflammatory cardiomyopathy 5
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P… Recruiting

2024-518710-11-00 Metastatic pancreatic ductal adenocarcinoma (mPDAC) 4 2023-06-12
Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 par… Recruiting

2024-517864-49-01 Autosomal Dominant Polycystic Kidney Disease 5 2020-09-08
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5